Andrew A. Quong, PhD
Associate Professor and Division Leader
Nanotechnology and Integrative Cancer Biology
Department of Oncology
Kimmel Cancer Center
Thomas Jefferson University
2013-2014 BCRF Project(s):
The goal of Dr. Quong’s BCRF-funded research is determining new strategies for patient treatment that include radiation therapy. By measuring the protein and gene expression in tumors and changes in proteins and metabolites in the blood, Dr. Quong aims to use this information for both choosing treatment and monitoring the patient’s response to treatment both for effectiveness and adverse side effects. In the coming year, in collaboration with BCRF grantee Dr. Richard Zellars at Johns Hopkins, Dr. Quong is proposing a new clinical trial examining the effectiveness of concurrent chemotherapy and partial breast irradiation in ER negative patients. In order to increase the rate of accrual, the researchers plan to include Thomas Jefferson University Hospital as a clinical site for the studies.
Dr. Quong has been active in the areas of nanoscience, surface physics, and materials science where his work was focused on calculating their fundamental properties to better understand structure function relationships. More recently, he was responsible leading the Systems Biology effort at Lawrence Livermore National Laboratory, and was the Deputy Director of the BioSecurity and NanoSciences Laboratory (BSNL), a basic research center. In this capability he was responsible for the oversight of the Systems Biology and Proteomics research areas.
In the proteomics area, he was responsible for bio-mass spectrometry efforts in the BSNL. This included as suite of complementary tools including an ion trap, a MALDI-TOF and a FTMS. He has successfully developed algorithms and software tools originally developed for large-scale systems studies such as chemical kinetics and applied them to biological systems such as calcium signaling. He has worked on the development of algorithms to analyze large "ohmic" datasets using fuzzy logic and multivariate analysis. His current work is in developing nanoscale platforms for cancer diagnostics and therapeutics along with systems biology and proteomic approaches to understanding the molecular mechanisms of disease.